Abstract
A Pseudomonas aeruginosa (P. aeruginosa) airway infection is one of the predominant causes contributing to the high morbidity and mortality rates in cystic fibrosis (CF) patients. The emergence of antibiotic resistant P. aeruginosa strains has led to an urgent need for new therapeutic approaches. Bacteriophages (phages) are viruses that can infect and lyse specific bacteria, providing a potential alternative approach in targeting antibiotic-resistant strains. We aim to isolate and characterise novel P. aeruginosa phages for combination in a cocktail to kill P. aeruginosa. One particular phage, PA4, could lyse 14/20 clinical isolates as observed through spot assays. This phage could significantly reduce the growth of bacteria in vitro, as determined through planktonic adsorption and inhibition assays as well as crystal violet- and LIVE/DEAD-stained biofilm assays. A morphological and genomic analysis revealed that PA4 belongs to the Myoviridae family and contained 66,450 bp. The broad infectivity profile, good stability in various pH and temperature conditions, lytic ability and the absence of the absences of antibiotic resistance, toxic and lysogenic genes suggest that PA4 is a good candidate for clinical grade use. Overall, phage therapy represents a promising alternative treatment option to antibiotics when treating a P. aeruginosa infection.
Highlights
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative bacterium, considered to be an opportunistic pathogen [1,2]
cystic fibrosis (CF) patients are frequently affected by chronic rhinosinusitis (CRS), in which colonisation of the paranasal sinuses with P. aeruginosa has been found to be a reservoir for a recurrent lung infection [1]
Treatment with systemic and inhaled broad-spectrum antibiotics from early in the life of those patients can lead to the development of antibiotic-resistant strains of P
Summary
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative bacterium, considered to be an opportunistic pathogen [1,2] It is ubiquitous in the environment and is frequently responsible for causing nosocomial infections in humans [1,2]. CF patients lack a functioning CF transmembrane conductance regulator gene, resulting in a change to the airway mucosa that is favourable to P. aeruginosa infection [2]. It is one of the first pathogens to infect and dominate the airways during a chronic infection and has been associated with worsening lung function in CF patients [2,3]. CF patients are frequently affected by chronic rhinosinusitis (CRS), in which colonisation of the paranasal sinuses with P. aeruginosa has been found to be a reservoir for a recurrent lung infection [1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
